Bausch Health Companies Inc. (BHC) Stock Price & Analysis
Bausch Health Companies Inc. (BHC) rose 1.17% to USD 5.17 as of June 10, 2026 at 02:19 UTC, according to Nexqual real-time market data.
BHC last closed at USD 5.11; the session ranged USD 5.09–5.26 on volume of 1,685,736 shares. Market capitalization is $1.93B, with a 52-week range of USD 4.93–8.69 (NYQ). Source: Nexqual, June 10, 2026 at 02:19 UTC.
Key Statistics (as of June 10, 2026 at 02:19 UTC)
| Price | USD 5.17 |
|---|---|
| Change | ▲ 1.17% (up) |
| Previous Close | USD 5.11 |
| Open | USD 5.17 |
| Day Range | USD 5.09 – 5.26 |
| 52-Week Range | USD 4.93 – 8.69 |
| Volume | 1,685,736 shares |
| Market Cap | $1.93B |
| Exchange | NYQ |
Technical Analysis (BHC)
Nexqual's technical model rates BHC "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:19 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 43.08 (neutral) |
| vs SMA50 | Below (USD 5.48) |
| MACD | -0.1 (negative) |
Analyst Ratings (BHC)
Wall Street analysts rate BHC "Hold" based on 6 analysts, with a mean price target of USD 7.5 (range USD 6–9), per Nexqual as of June 10, 2026 at 02:19 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 7.5 |
| High Target | USD 9 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 1 / 8 / 0 |
Earnings (BHC)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 1.01 |
| Revenue Estimate | $2.66B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.78 vs est 0.69 ▲ beat |
| 2025-12-31 | USD 1.1 vs est 1.26 ▼ miss |
| 2025-09-30 | USD 1.16 vs est 1.06 ▲ beat |
| 2025-06-30 | USD 0.91 vs est 0.94 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financials & Fundamentals (BHC)
| Total Revenue | $10.53B |
|---|---|
| Revenue Growth (YoY) | +11.70% |
| Gross Margin | +71.04% |
| Operating Margin | +20.64% |
| Profit Margin | -11.47% |
| Current Ratio | 1.32 |
| Total Cash | $1.30B |
| Total Debt | $20.80B |
| Free Cash Flow | $1.12B |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Financial Health Score (BHC)
Nexqual rates Bausch Health Companies Inc.'s overall financial health "Solid" across five dimensions, as of June 10, 2026 at 02:19 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 71%, operating 21% |
| Balance Sheet | Mixed — $1.30B cash vs $20.8B debt |
| Cash Flow | Solid — FCF $1.12B, 11% margin |
| Efficiency | Mixed — No data |
Ownership (BHC)
| Insider Ownership | +10.89% |
|---|---|
| Institutional Ownership | +65.11% |
| Shares Outstanding | 373.48M |
| Float | 260.45M |
| Short % of Float | +2.05% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
Leadership (BHC)
Bausch Health Companies Inc. is led by Thomas J. Appio (age 63), CEO & Director, per Nexqual as of June 10, 2026 at 02:19 UTC.
| CEO & Director | Thomas J. Appio (age 63) |
|---|---|
| Executive VP & CFO | Jean-Jacques Charhon (age 60) |
| Executive Vice President of US Pharma | Aimee J. Lenar (age 49) |
| Executive VP & COO | Mirza Dautbegovic |
| Senior Vice President of Europe & Canada | Cees Heiman |
Major Backers & Investors (BHC)
Notable institutional backers of Bausch Health Companies Inc. include PAULSON & CO. INC., Goldentree Asset Management LP, Royal Bank of Canada, according to Nexqual as of June 10, 2026 at 02:19 UTC.
Active Investors
| Investor | Stake |
|---|---|
| PAULSON & CO. INC. | 19.59% |
| Goldentree Asset Management LP | 9.27% |
| Royal Bank of Canada | 3.04% |
| Nomura Holdings Inc. | 2.4% |
| Healthcare of Ontario Pension Plan Trust Fund | 2.14% |
| MFN Partners Management, LP | 1.6% |
| Kohlberg Kravis Roberts & Co. L.P. | 1.4% |
| Goldman Sachs | 1.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.88% |
Source: Nexqual, June 10, 2026 at 02:19 UTC.
From Bausch Health Companies Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
- It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
- The company develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health.
- The company sells its products in the United States, China, Canada, Poland, Mexico, France, South Korea, Russia, Japan, Germany, the United Kingdom, Spain, Italy, and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELAN | Elanco Animal Health Incorporat | USD 24.5 | ▲ 3.68% |
| BLCO | Bausch + Lomb Corporation | USD 15.65 | ▲ 1.23% |
| BHVN | Biohaven Ltd. | USD 11.09 | ▲ 2.69% |
| CPRI | Capri Holdings Limited | USD 19.94 | ▲ 5.67% |
| GDRX | GoodRx Holdings, Inc. | USD 2.65 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:19 UTC. This page is informational and not investment advice.